Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Multi-center and Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma

NCT02856815 is registered in ClinicalTrials.gov with GC Cell Corporation as lead sponsor.

NCT NCT02856815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02856815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Multi-center and Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma
Lead sponsor
GC Cell Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2018
Completion date
September 22, 2022
Enrollment
76 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular